Core Insights - Polyrizon Ltd. has rebranded its lead intranasal allergy product to NASARIX™, marking a significant step towards potential commercialization [1] - The global market for allergic rhinitis treatments is projected to grow from approximately USD 13.08 billion in 2025 to USD 18.81 billion by 2035, with a CAGR of 3.7% [1] - NASARIX™ utilizes a unique hydrogel technology to create a barrier that physically traps allergens, offering a drug-free alternative to traditional allergy treatments [1] Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions [1] - The company is currently conducting a human factors and usability study to validate the product's instructions and user experience, aligning with FDA guidance [1] - Polyrizon plans to initiate clinical trials for NASARIX™ in Q3 2026, positioning it as a medical device for a more streamlined approval process [1] Industry Context - Allergic rhinitis affects an estimated 10–30% of the global population, with over 60 million people in the U.S. impacted annually [1] - The demand for intranasal therapies and non-sedating alternatives is driving market growth, as most current treatments are reactive rather than preventive [1] - NASARIX™ aims to fill a gap in the market by providing a proactive, user-friendly solution for allergy sufferers [1]